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INVESTIGATION OF PRONIOSOMES GEL AS A PROMISING CARRIER FOR 
TRANSDERMAL DELIVERY OF GLIMEPIRIDE. 
ABSTRACT: 
The aim of the study was to develop a proniosomal carrier system that is capable 
of efficiently delivering entrapped glimepiride over an extended period of time for the 
treatment of type 2 diabetes. Proniosomal gels were developed based on Span 60 with 
and without cholesterol. The entrapment efficiency ofdrug inside niosomes developed 
from hydration of the proniosomes gel was also characterized. The in vitro release and 
skin permeation of glimepiride from various proniosome gel formulations were 
investigated. The stability studies were performed at 4°C and at room temperature. The 
maximum entrapment efficiency was obtained when the cholesterol concentration was 
10% of total lipid (90.02%). In vitro release through Mixed Cellulose Estermembrane 
showed sustained release of drug from proniosomes gels. In vitro drug permeation across 
rabbit skin revealed improved drug permeation and higher transdermal flux with 
proniosomes gels compared to hydro-alcoholic gel of drug. Also, good physical stability 
was also achieved with proniosomes gels. Kinetics of in vitro skin permeation showed 
diffusion model of drug release from formulations. The study proved that the 
concentration of cholesterol had great influences on the properties of proniosomes gels. 
Hence, preparation containing 10% cholesterol can significantly increase trans-epidermal 
flux and prolong the release of glimepiride. 
KEYWORDS: Cholesterol, Glimepiride,Proniosomes gel, Span 60, Sustained release, 
Transdermal drug delivery. 
INTRODUCTION: 
The transdermal mode offers several distinct advantages; the skin presents a 
relatively large and readily accessible surface area for absorption, Further benefits of  
transdermal drug delivery (TDD) include the potential for sustained release, Provides the 
ease of termination, if need arises (e.g. systemic toxicity) with less pain sensation
1
 and 
avoiding the first pass hepatic metabolism
2
. 
The self-assembly of non-ionic amphiphiles in aqueous media is resulting in 
closed bilayer structures called niosomal vesicles or niosomes
3
. They are analogous to 
liposomes (phospholipids vesicles) and can encapsulate both hydrophilic and lipophilic 
solutes, hence, serve as drug carriers
4
. Among all routes of administration, the enhanced 
transdermal delivery of niosome encapsulated drugs was seriously considered. 
Transdermaldrug delivery with niosomes appear promising for hydrophobic 
andamphiphilic drug molecules and would require that the dose to be appliedin high 
concentration and within niosomes prepared from low phasetransition surfactant 
mixtures
5
.  
Moreover, for transdermal application, niosomal vesicles should be included into 
polymeric matrix like methylcellulose gels. However, the use of polymeric matrix in the 
formulation may affect drug penetration and niosome integrity
6
. This problem in addition 
to the physical instability of the niosomal dispersion can be circumvented by the 
formulation of liquid crystalline compact proniosomes gels or alcoholic solutions of the 
nonionic surfactant. Both of them are of great stability due to very little water content. 
Previously, proniosomes have been introduced as a stable form alternative to the 
liquid formulations of niosomes, offering advantages in terms of formulation stability and 
 shipping expenses
7
. They transform into niosomal vesicles immediately upon hydration, 
hence, they are called proniosomes
8-10
. The great advantage offered by proniosomes is 
their ease of use and their hydration is much easier than the time consuming shaking 
process required to hydrate surfactants in the conventional dry film method
11
. 
Furthermore, unacceptable solvents are avoided in proniosomes formulations. The 
systems may be directly formulated into transdermal patches and doesn't require the 
dispersion of vesicles into polymeric matrix
12
. 
Glimepiride (GMD), a 3
rd
 generation sulfonylurea drug used for treatment of type 
2 diabetes. Clinical studies have proven GMD to be safe and effective in reducing fasting 
and postprandial glucose levels, as well as glycosylated hemoglobin concentrations, with 
dosages of 1–8 mg/day. GMD has been associated with severe and sometimes fatal 
hypoglycemia and gastric disturbances like nausea, vomiting, heartburn, anorexia, 
hemolytic anemia due to the transient high blood concentration that occurs after oral 
administration and increased appetite after oral therapy
13
. GMD has a relatively short 
elimination half-life (5 h), thereby requiring twice or thrice daily dosing in patients, Since 
these drugs are usually intended to be taken for a long period, patient compliance is also 
very important
14
.To circumvent these drawbacks GMD was entrapped in vesicular carrier 
system to improve therapeutic efficacy of GMD via transdermal route. 
 The purpose of this study to develop GMD proniosomes carrier systems using the 
common, non-irritant, safe and available non-ionic surfactants Span 60 with and without 
cholesterol and to investigate the possibility of using proniosomes gels for transdermal 
delivery of GMD. 
MATERIALS AND METHODS: 
MATERIALS: 
GMD was a kind gift from Medical Union Pharmaceuticals, Abu Sultan, Ismailia, 
Egypt; Sorbitanmonostearate (Span 60), Cholesterol (> 99%), Sodium azideand Hydroxy 
Propyl Methyl Cellulose (HPMC; MW 86,000 Da, viscosity of 2% solution 4000 cP)were 
procured from Sigma-Aldrich, St. Louis, MO, USA.All other chemicals and solvents 
were of analar grade and obtained from El-Nasr Company for pharmaceutical chemicals, 
Cairo, Egypt. 
METHODS: 
Preparation of Proniosomes gels 
Proniosomes gels were prepared by the Coacervation phase separationmethod 
previously repoerted
15
. In glass vials accurately weighed amountsof Span 60 were mixed 
with the calculated amount ofcholesterol. The cholesterol was added as 0%, 10%, 
30%and 50% of totallipids. Absolute ethanol (about 400 mg) was added to thesurfactant 
or surfactant/cholesterol mixtures. Precisely, surfactants: alcohol (1:1) then vials were 
tightly sealedand warmed in water bath (55-60 °C) for 5-10 min while shaking 
untilcomplete dissolution of cholesterol. To each of the formed transparentsolutions, 
about 0.16 ml hot distilled water (55-60°C) was added while warming in the water bath 
for 3-5 min till a clear or translucent solution was produced. The mixtures were allowed 
to cool down at room temperature and observed for the formation of white creamy 
proniosomal gel (Table 1). The obtained formulations were kept in the same closed glass 
vials in dark for further characterization
15
. 
Drug loading into proniosomesgels 
GMD was added as (5, 10, 12, 15, 17and 20 mg) to the nonionic surfactant/ 
cholesterol mixture (400mg) and dissolved by the aid of absolute ethanol while warming 
 at 50-60°C in water bath. It was noted that the addition of the drug didn't show turbidity 
or precipitated crystals in preparations. 
Table 1. Formulation design and characterization parameters of proniosomes gels. 
Formula 
Code 
Formula Composition Characterization 
Parameters 
GMD 
Conc. 
(mg) 
Span 60 
Conc. 
(mg) 
Cholesterol 
Conc. 
(mg) 
Ethyl 
alcohol 
(mg) 
Physical 
Appearance 
Entrapment 
Efficiency 
%* 
P6 15 400 0 400 White 
creamy gel  
89.07±0.21 
P6A 15 360 40 400 White 
creamy gel 
90.02±0.23 
P6B 15 280 120 400 White 
creamy gel 
87.56±0.30 
P6C 15 200 200 400 White 
creamy gel 
86.88±0.70 
* Each result is the mean ± SD. (n = 3) 
Hydration step and formation of niosomes 
About 7 ml of phosphate buffer (pH 7.4) were added into each vial followed by 
heating for 10 minat a temperature 60°C±3 in a water bath while vortexing. The final 
volume was adjusted to 10 ml by the same buffer
15
.  
Preparation of 50%alcoholic HPMC gels containing GMD 
Weighted amount of HPMC-4000 cP were dispersed in distilled water containing 
50% ethyl alcohol and stirring sufficient time (about 30min) was allowed for complete 
hydration and gel formation, then weighted amount of GMD was added and dispersed 
thoroughly. The concentration of HPMC-4000 cp was 2% and the final concentration of 
GMD was adjusted to be 15mg/gm. 
Characterization of proniosomes gel bases 
Total drug content 
1 ml of aqueous dispersionwas disrupted using sufficient quantity of methyl 
alcohol
16
and the absorbance was recorded at 228 nm. 
 
Microscopic examination 
Light microscopy 
A thin layer of proniosomes gel were spread on a glass slide, and examined for 
the gel structure and the presence of insoluble drug crystals using ordinary light 
microscope with magnification powers (40 X). Photomicrographs were taken for either 
proniosomal gel or niosomes
12
. 
Transmission electron microscopy (TEM) 
Transmission electron microscopy (JEOL-JEM-2100, Tokyo, Japan) was 
performed to investigate the morphology of niosomes.A drop of the diluted dispersion 
was applied to a carbon-coated 300 mesh copper grid and left for 1min to allow some of 
the niosomes to adhere to the carbon substrate. The remaining dispersion was removed by 
absorbing the drop with the corner of a piece of filter paper and the sample was air 
dried
17
. 
Fourier transform-infrared spectroscopy (FT-IR) studies 
 The FT-IR spectral analysis was conducted to verify the possible chemical 
intermolecular interactions between GMD, Span 60 and cholesterol. The samples were 
scanned using FT-IR spectrophotometer, Nicolet 200 FT-IR, USA in the spectral region 
between 4000 and 400 cm
-1
. The smoothing of the spectra and the baseline correlation 
procedures were applied. The detector was purged with dry nitrogen gas to reduce 
moisture and to increase the signal level. 
Differential scanning calorimetry (DSC) 
The thermotropic properties of the samples were explored to assess the degree of 
crystallinity and the presence of possible interactions between GMD, Span 60 and 
cholesterol. DSC was performed with a DSC Q2000 V24.4 Build 116. The calorimeter 
was calibrated for temperature and heat flow accuracy using the melting of pure indium 
(mp156.6°C and ΔH of 25.45 J gm−1). The temperature range was from 0 to 300°C with a 
heating rate of 10°C/min. The gas used was nitrogen with a purging rate of 50 ml/min. 
The weight of each sample was 5-9 mg. 
Determination of entrapment efficiency of GMD in niosomes by Freez-thawing/ 
Centrifugation method 
1 ml Samples of niosomes dispersion were frozen for 24 h at 20°C in Eppendorf 
tubes. The frozen samples were removed from the freezer and let to thaw at room 
temperature, then centrifuged at 20000 rpm for 60 min at 4°C. Two times washings with 
phosphate buffer (pH 7.4) were done for complete removal of drug adsorbed on the 
surface of niosomal vesicles. The supernatant was separated each time from niosomal 
pellets and prepared for the assay of free drug
15
. Each result was the mean of three 
determinations (±SD).The drug content was determined spectrophotometrically at 228nm 
against phosphate buffer (pH 7.4) as blank. The %of GMD entrapped was calculated by 
subtracting amount of un-entrapped drug from the total drug incorporated
18
. 
% Encapsulation efficiency 
                           
                    
     
Assessment of GMD release rates from proniosomesacross mixed cellulose ester 
(MCE)membrane 
The release of GMD from different proniosomes gelswere determined using 
modified Franz cell fabricated locally with 6.6 cm
2
 of diffusion area. MCE membrane 
(0.45μm pore size), previously soaked in phosphate buffer (pH 7.4),was mounted 
between the donor and receptor compartments of the diffusion cells. The proniosomes 
gels were placed on MCE membrane in the donor chamber whilst phosphate buffer 
containing 10% methanol (pH 7.4) was used as a receiver medium in the receptor 
chamber. The temperature was kept at 32± 0.5 °C and the stirring rate was 100 rpm in 
Kottermann shaker (D3165 Hangisen, Germany). About two milliliter samples were 
withdrawn at specified time intervals (0.5, 1, 2, 3, 4, 6, and 8 h) and replaced with equal 
volumes of fresh receiver medium to keep the volume constant during the experiment. 
Samples were analyzed spectrophotometrically at 228 nm against samples collected from 
diffusion of drug free systems as blank.  
Assessment of GMD release rates from niosomes 
The niosomal pellets were resuspended in 50 ml of phosphate buffer (pH 7.4). 
The suspension was placed in a stoppered glass flask in a shaking water bath at 37°C. 1 
ml samples were withdrawn at the following intervals; 0, 1, 2, 3, 4, 6 and 8 h after 
incubation. Samples were centrifuged as before and supernatants assayed at 228nm. The 
percentage of drug release was plotted as a function of time
15
. 
 Ex vivo skin permeation study 
Abdominal skin of male rabbits (2-2.5 kg) was used in the study. Hair was 
removed from the abdominal skin with the aid of an electric animal clipper and shaver. 
Care was taken not to damage the skin surface. Rabbits were sacrificed and the 
abdominal skin of the rabbit was separated. Sodium azide (0.02%) is applied to the skin 
as preservative and the skin was stored at -20°C and used within three days for the 
permeation study. The permeation experiments were run by using the same diffusion 
cells previously described in the release through MCE membrane. However, skin 
membranes were mounted, with the stratum corneum side towards the donor (drug loaded 
system) and the dermal side facing and in contact the receptor compartment which 
contain phosphate buffer containing 10% methanol (pH 7.4) maintained at 32±0.5°C
19
and 
the stirring rate was 100 rpm in Kottermann shaker.  
Proniosomes gels of Span 60 and alcoholic HPMC were applied to the stratum 
corneum side. 2 ml aliquots were sampled at 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hr after 
starting the experiment from the receptor medium and replaced with equal volume of the 
fresh receiver medium. Samples were analyzed spectrophotometrically at 228 nm using 
samples collected from permeation of drug free systems as a blank. Each experiment was 
carried out in triplicate. 
All skin permeation parameters such as steady state transdermal flux (SSTF), 
permeability coefficient (PC), maximum diffusion (Dmax) and diffusion coefficient (D) of 
GMD across rabbit skin were estimated for different formulations. Permeability 
parameters of GMD were constructed by plotting the cumulative amount of the drug 
permeated per unit area (Q) as a function of time. The steady state flux (JSS) was 
calculated from the slope. The permeability coefficient (PC) was calculated by dividing 
the flux by the initial drug load (Co).The diffusion coefficient (D) was calculated by 
plotting the cumulative amount of drug permeated versus square root of time     
according to Equation
13
. 
Q=2Co (Dt/  )
 ½   
(Higuchi model). 
Assessment of physical stability for proniosomes gels 
Proniosomes gels stability and aggregation of niosomes dispersions as a function 
of temperature were determined as the change in total drug content and entrapment 
efficiency after storage. The proniosomal gels and niosomes dispersions were stored in 
glass vials at room temperature or kept in refrigerator (4°C) for 3 months
17
.  
Statistical analysis 
The data were reported as mean ± SD (n = 3) and statistical analysis of the data 
were carried out using one-way ANOVA at a level of significant of P< 0.05. 
RESULTS AND DISCUSSION: 
Formation of proniosomes gels 
A sol phase of Proniosomes gelswere formed when distilled water (about 30-40% 
w/w of total lipids) at 60°C is added in drops to the nonionic surfactant dissolved into hot 
absolute ethanol while vortexing, where the temperature was kept at 60°C. Since the 
solvent (absolute ethanol) amount is small and the formation of micelles is not possible 
into this solvent, it is expected that the addition of small amount of water favors the self-
assembly of the surfactant into w/o microemulsion sol phase, where the aqueous droplets 
bound by surfactant interfacial films which are dispersed in the continuous solvent 
phase
20
.  
 Cooling the sol phase results in a decrease in the solubility of Span 60 and 
cholesterol in the solvent and consequently, lower solvent- cholesterol affinities due to 
the limited solvent system present. The formed gel structure proposed to be amphiphilic 
system comprising double layers of oriented molecules placed head to head and tail to tail 
with water present as droplets or sheets of water molecules between the hydrophilic 
residues of the surfactant layers. Span 60 (Tc=53°C) produced white creamy gel in the 
presence or absence of cholesterol as it has the greatest transition temperature and is solid 
at room temperature, so it acts as gelator by itself. The formed proniosomes gels is 
thermo-reversible as an increase in temperature results in the solvation of the gelator into 
the solvent and returns again to the gel structure upon cooling
15
. 
Hydration of proniosomes gels 
Niosomes are formed only when the proniosomes gels comes into contact with an 
aqueous environment such as moisture found on the skin or mucosal surfaces. The 
contact of proniosomes gels with water leads to swelling of the lamellar liquid crystal 
bilayers and vesicles due to the interaction of the hydrophilic head groups of the 
surfactant with water molecules. The surfactant tubules serve as conduits for water 
penetration into the gel network and the gel fragments
21
.  
The complete hydration of proniosomes gels was found to take long time ranging 
from 1h to 2h at room temperature with continuous stirring or vortexing. So, warming the 
gel with excess water above the transition temperature of Span 60 (>60°C) accelerates the 
transformation to niosomal structures within 5-10 min only. 
Drug loading in proniosomes gels 
15 mg of GMD was found to be completely dissolved into proniosomes gels. This 
is perhaps due to high solubility of the drug in surfactant/cholesterol/ethanol mixture. 
Microscopic examination showed no drug crystals precipitated. 
Drug content 
The drug content of the developed formulations was not found to be significantly 
different (P< 0.001) from the added amount. 
Microscopic examination 
Gel structure 
The gel structures were formed fromfloccules of small tubular and vesculating 
particles which have creamy opaque appearance and also no drug precipitates (Figure 1). 
The units of the gel are often bound together by van der Waals forces so as to form 
crystalline regions throughout the entire system. The dominant coherent gel phase is built 
up by surfactant/cholesterol lamellae with water phase mainly bound interlamellarly to 
the hydrophilic head groups of surfactant/ cholesterol lamellae. This resulted in an 
interconnected network of a mixture of lamellar liquid crystals resembling palisades or 
tubular aggregates and vesculating lamellae
12
. 
Niosomes dispersions: 
Niosomes dispersionsunder ordinary microscope gave rise to randomly scattered 
spherical structures comprising multilamellar and Multivesicular vesicles (Figure 2). The 
examined niosomes appeared as small unilamellar, spherical nano-vesicles under TEM 
(Figure 3). 
FT-IR studies 
The FT-IR spectra of GMD, Span 60, cholesterol and physical mixture are 
displayed in Figure 4. The GMD showed strong absorption peak at 1159 cm
-1
 
corresponding to the sulphonamide group (S=O) and peaks at 1696 cm
-1
 corresponding to 
 carbonyl group (C=O). The broad bands at 3374 cm
-1
and 3377cm
-1
could be assigned to 
O—H stretching vibrations of Span 60 and cholesterol, respectively. The FT-IR spectrum 
of the physical mixture revealed that the characteristic bands of GMD did not disappear 
or exhibit major shifts. Furthermore, no new bands were formed. These findings pointed 
out the lack of considerable intermolecular interactions between GMD, Span 60 and 
cholesterol. 
Differential scanning calorimetry (DSC) 
DSC is a fast and reliable method to screen drug-excipient interactions as 
indicated by appearance of a new peak(s), change in the peak shape and its onset, peak 
temperature/ melting point and relative peak area or enthalpy. Figure 5 depicts various 
DSC thermograms obtained during the study. Pure GMD showed a sharp endothermic 
peak at 205.72°C. Thermogram of Span 60 exhibits an endothermic peak with onset at 
44.62°C and maximum occurrence at 52.24°C. Cholesterol is reported to show an 
endothermic peak at 148-150°C. It is evident that the original peaks of GMD disappear 
from the thermogram of proniosomal gel (containing Span 60, Cholesteroland GMD or 
Span 60 and GMD). These observations confirm incorporation of GMD into proniosomal 
gel proving complete entrapping of drug into the vesicles. 
Factors affecting entrapment efficiency of glimepiride in niosomes dispersions 
Effect of cholesterol  
Cholesterol is one of the common and essential additives in niosomesdispersions 
in the present study. Incorporation of cholesterol was known to influence vesicle stability 
and permeability
22
. The effect of cholesterol on GMD entrapment was varied according 
to its concentration. A significant increase (P < 0.05) in the entrapment efficiency of 
GMD was obtained when 10% of cholesterol was incorporated into niosomes prepared 
from Span 60 (P6A) followed by a decrease in entrapment efficiency of the drug upon 
further increase in cholesterol content (Table 2).  
Reason revealed for this type of behavior is cholesterol molecules accommodate 
itself as ‘‘vesicular cement’’ in the molecular cavities formed when surfactant monomers 
are assembled into bilayers to form niosomal membranes and this space filling action 
results in the increased rigidity and the improved entrapment efficiency. On further 
increase of cholesterol beyond certain concentration it compete with the drug for the 
space within the bilayers, hence excluding the drug and can disrupt the regular linear 
structure of vesicular membranes
23
.  
In vitro release studies 
Figure 6 showed the percentage GMD released from proniosomes gels over 8 h. 
From the obtained results it is clear that P6 showed the lowest release rates among all 
proniosomal preparations. Addition of 10% cholesterol (P6A) gave greater release rates 
than those without cholesterol. Increasing cholesterol content up to 50% was 
accompanied by gradual decrease in the release rate, however, remained significantly 
higher than that of cholesterol free systems (P< 0.05). This could be due to the fact that 
the addition of cholesterol appeared to disrupt the ordered array of the hydrocarbon 
chains in the gel phase
15, 24
. Below the transition temperature, addition of cholesterol 
made the membrane less ordered, while above the transition temperature made the 
membrane more ordered
25, 26
. At 37°C P6 gave rise to highly ordered gel phase than those 
containing cholesterol, consequently, they produced lower release amounts of GMD. 
Kinetic analysis of the release data of GMD Proniosomal systems 
 The kinetic analysis of GMD release data from different Proniosomes gels were 
tested according to zero, first order kinetic and diffusion controlled model. The results 
clearly revealed that all proniosomal systems fitted better with Higuchi diffusion model. 
Glimepiride release rates from niosomes 
The release profiles of GMD from niosomes of different cholesterol contents is an 
apparently biphasic release process. Rapid drug leakage was observed during the initial 
phase where about 30–35% of the entrapped drug was released from various formulations 
in the first hour. However, during the following 8 ha slow release occurred in which only 
further 3% to5% of GMD was lost from different niosomal preparations (Figure 7). This 
could be explained on the basis that the drug is mainly incorporated between the fatty 
acid chains in the lipid bilayers of niosomal vesicles. This leads to rapid ionization and 
release upon dispersing niosomes in increased buffer (pH 7.4) volumes until reaching 
equilibrium
27
. 
Figure 7 showed that P6A displayed the lowest extent of drug release after 8h. 
The percent GMD released from P6A & P6Cafter 8 h was 34.54% and 39.08%, 
respectively. The increase in release rates of GMD from P6C formulation was 
statistically significant (P< 0.05) compared to P6 and P6A formulation. This result 
attributed to the cholesterol concentration.10% cholesterol produced an optimum 
hydrophobicity that decreased the formation of the transient hydrophilic holes, 
responsible for drug release through liposomal layers
28
. On the other hand, further 
increase in cholesterol amounts into niosomes formulations could increase the release of 
GMD
23
. 
Ex vivo skin permeation studies 
After 24 h about 213.19, 187.37, 203.18 and203.58 μg/cm2were permeated across 
rabbit skin from P6A, P6, P6B, and P6C proniosomal formulations respectively as 
showed in figure 8. Addition of 10% cholesterol (P6A) significantly enhanced GMD 
permeability from proniosomes gel (P<0.05). 
The steady state transdermal fluxes (SSTF) of GMD from P6A (7.339 µg/cm
2
.hr) 
higher than SSTF ofGMD from P6, P6B and P6C (6.356, 6.560 and 6.306 µg/cm
2
.hr 
respectively) and five times more than alcoholic HPMC (Table 2). Statistical analysis 
showed a significant difference between SSTF of P6A and other formulations.  
The reduced permeation of GMD from proniosomal gels of Span 60 is primarily 
attributed to its high transition temperatures which made them in a highly ordered gel 
state at the permeation temperature (32°C)
19
.  
Table 2. Permeability parameters of GMD released across rabbit skin. 
Formula 
Code 
Permeability Parameters 
Dmax (µg) JSS (µg/cm
2
.hr) PC (cm/hr) (D) 
Alc.HPMC 454.41 2.031 3.692×10
-4 
4.121×10
-6 
P6 1236.63 6.356 1.155×10
-3 
3.836×10
-5
 
P6A 1407.02 7.339 1.334×10
-3
 5.131×10
-5
 
P6B 1341.01 6.560 1.238×10
-3
 4.334×10
-5
 
P6C 1343.59 6.306 1.146×10
-3
 4.060×10
-6
 
Dmax: maximum amount of drug permeated,JSS: steady state flux, PC: permeability 
coefficient and D: diffusion coefficient 
Kinetic analysis of the permeation data of GMD Proniosomal systems 
The kinetic analysis of the permeation data of GMD from different proniosomal 
systems were tested according to zero, first order kinetic and diffusion controlled model. 
 The results clearly revealed that all proniosomes gels fitted better with the diffusion 
controlled model. 
Physical stability 
The results of stability studies were compiled in Figures 9-12. The effects of 
storage temperature on entrapment efficiency were expressed as % of GMD retained 
entrapped according to the following equation. 
                       
                                   
                                    
      
Generally, drug leakiness from niosomal dispersions upon storage in refrigerator 
was significantly low; while at room temperature there was an appreciable drug loss and 
decreased in entrapment efficiency. Hence the niosomes dispersions needs to be 
refrigerated for use as is the case with all other vesicular systems
17
. 
Proniosomes gels were more stable than niosomal vesicles under refrigerated and 
room temperature condition. This suggests that proniosomes offered a more stable system 
that could minimize the problems associated with conventionally prepared niosomes like 
degradation by hydrolysis, or oxidation, sedimentation, aggregation and fusion during 
storage. P6A (1.86% loss in drug content and 5.89% decrease in entrapment efficiency) 
were more stable than other formulations at 3 months. 
CONCLUSION: 
Concluding the above mentioned results; Proniosomes gels could enhance the 
solubility of certain poorly soluble drugs but to a maximum limit after which any increase 
in the drug concentration may lead to drug precipitation.The EE% of GMD (as a model 
for poor soluble drugs) into niosomes prepared by the proniosomal method was a 
function of cholesterol content.Cholesterol content affected the drug release and 
permeation properties of proniosomal system.All proniosomal gels fitted to diffusion 
model when using MCE membranes and when using rabbit skin for release and 
permeation studies, respectively.It is clear that niosomal formulations containing 10% 
cholesterol are the most stable among other tested formulations. 
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Figure 1: Photomicroscopic view of proniosomal gels: (a) P6 (b) P6A (c) P6C.    
 
Figure 2: Niosomal vesicles photomicrographs of (a) P6 (b) P6A 
 
Figure 3: TEM micrographs of niosomal vesicles at 60000x magnification power. 
 
 
  
Figure 4: FT-IR spectra of (a) GMD, (b) Span 60, (c) Span 60 and GMD and (d)Span 60, 
GMD and Cholesterol. 
 
 
Figure 5: DSC thermogram of (a) GMD, (b) Span 60, (c) Proniosomes gel of Span 60 and 
GMD and (d) proniosomes gel of Span 60, GMD and Cholesterol. 
  
  
Figure 6: Effects of cholesterol on the in-vitro release of GMD from proniosomes gels. 
 
 
 
Figure 7: In vitro release of GMD from niosomes after incubation in phosphate buffer pH 
7.4. 
 
 
Figure 8: Effects of cholesterol content on GMD permeability across rabbit skin.  
 Figure 9: GMD content in proniosomes gels after storage for 3 months (a) at 4°C (b) at 
25°C. 
Figure 10: GMD content in proniosomes dispersions after storage for 3 months (a) at 4°C 
(b) at 25°C. 
 
Figure 11: % GMD retained in proniosomes gels after storage for 3 months (a) at 4°C (b) 
at 25°C. 
 Figure 12: % GMD retained in proniosomes dispersions after storage for 3 months (a) at 
4°C (b) at 25°C. 
 
 
